Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Therapeutic Drug Monitoring|March 19, 2013
Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146Xinyan Zhang, Camlin Tierney, Mary Albrecht, et al.
Jacobs Journal of AIDS/HIV|February 16, 2016
PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150Beverly E Sha, Camlin Tierney, Xin Sun, et al.
Open Forum Infectious Diseases|March 4, 2015
Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trialSamir K Gupta, Douglas Kitch, Camlin Tierney, et al.
AIDS (London, England)|March 19, 2014
Impact of randomized antiretroviral therapy initiation on glucose metabolismKristine Mace Erlandson, Douglas Kitch, Camlin Tierney, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2017
Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B StudyRobert A Parker, Dustin J Rabideau, Paul E Sax, et al.
Clinical Trials (London, England)|March 20, 2020
Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regionsKonstantia Angelidou, Mary Glenn Fowler, Pat Flynn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 14, 2014
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudineChristina M Wyatt, Douglas Kitch, Samir K Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 22, 2011
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224sGrace A McComsey, Douglas Kitch, Paul E Sax, et al.
The Journal of Infectious Diseases|May 25, 2011
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202Grace A McComsey, Douglas Kitch, Eric S Daar, et al.
The Journal of Infectious Diseases|November 14, 2012
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202Heather J Ribaudo, Eric S Daar, Camlin Tierney, et al.
Pageof 7